🔗 Share this article

As America proceeds with sweeping adjustments to its vaccination recommendations, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning coronavirus vaccines during the global health crisis and has zeroed in on possible deaths after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Schedule

Health officials were set to announce radical changes to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would place the US out of alignment with many the global community with insufficient data for improved outcomes. This reveal has been pushed back until the coming year.

In place of the top vaccines chief, Høeg is scheduled to speak at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to run the division this calendar year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine branches as Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for ending specific pediatric vaccine recommendations in the US to become more like the Danish model, a nation with universal health coverage and a citizenry about the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has little discernible experience in pharmaceutical research, approval processes or management, which has been typical for former directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a major agency. She lacks background in industry regulation.”

Previous heads of the center would “grasp laws and regulations and the underlying principles of drug development”, noted Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division clears thousands of generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and each of these must be looked after,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

There is also, a substantial management component to the job, which manages over 5,000 personnel. “It is a huge administrative position, if you execute it properly,” the former official concluded.

Official Statement and Contentious Policies

In response to inquiries about Dr. Høeg's qualifications and whether this selection signifies more teamwork among agency officials on vaccines, a spokesperson stated that the “questions stem from incorrect premises”.

“Her experience aligns with the duties of her role,” the official explained, pointing to the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed one-day therapy clearance system that apparently worried her preceding directors. “How are these therapies being picked for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, except for shots.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more established, if concerning, track record, some experts have noted. She authored a research paper using non-validated public submissions to determine the frequency of heart inflammation after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the new federal leadership included altering regulations for novel immunizations and ending “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She is an complete dogmatist who begins with her conclusions and reverse-engineers to accommodate the data in a highly deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of fellow skeptics, {like|